SINGAPORE, May 31 (Bernama-GLOBE NEWSWIRE) — Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced two presentations featuring clinical data from the company’s autologous CD30.CAR-T therapy TT11 and off-the-shelf CD30 CAR EBVST therapy (TT11X) will be featured at the 17th International Conference on Malignant Lymphoma taking place from June 13-17, 2023, at Lugano, Switzerland.
TT11, is Tessa’s autologous CD30.CAR-T therapy currently being investigated in combination with Nivolumab in a Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients. A poster providing first peak into data from this combination study will be presented at ICML, 2023.